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SURAMIN PROTECTS FROM CISPLATIN-INDUCED ACUTE KIDNEY INJURY 
 
Tess V.Dupre 
July 1, 2015 
 
In rodent models, suramin improves recovery following acute kidney injury (AKI). We 
hypothesized that suramin would be useful in protection against cisplatin-induced AKI.  
This hypothesis was tested by pre-treating C57BL/6j mice with suramin prior to cisplatin. 
Our data indicates that suramin protects the kidney from injury by decreasing cisplatin-
induced decreases in kidney function. Renal histology indicated that suramin 
significantly protected from cisplatin-induced AKI. Data indicate that suramin 
pretreatment attenuated mRNA expression of pro-inflammatory cytokines and 
chemokines following cisplatin treatment, while also decreasing markers of cell stress 
and cell death. We utilized the same experimental design with 10-month old FVB mice 
expressing mutant Kras driven lung adenocarcinomas. Assessment of lung histology 
and kidney function indicated that suramin protected mice from cisplatin-induced AKI 
and did not inhibit cisplatin’s anti-tumor efficacy. These results suggest that suramin 
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The kidneys are responsible for many essential physiological functions, including the 
following: filtration and elimination of metabolic and toxic wastes from the blood; 
regulation of the internal fluid environment to maintain proper fluid volume and tonicity, 
pH balance, and electrolyte composition; essential endocrine functions such as 
erythropoiesis and blood pressure regulation; and the metabolism and excretion of many 
drugs. A rapid loss in kidney function, commonly referred to as acute kidney injury (AKI), 
can result in a myriad of clinical manifestations and sequelae (1). Unfortunately, there is 
currently no single definition of AKI, but rather multiple slightly different and widely used 
definitions of AKI. While all of the accepted clinical definitions of AKI monitor changes in 
serum creatinine and urine output to diagnose and classify the severity of clinical 
presentations of AKI, the actual diagnosis and prognosis of each AKI case will differ 
slightly amongst clinics depending on the definition utilized (1). The incidence of AKI is 
more than 5,000 cases per million per year for non-dialysis-requiring patients, and the 
incidence of AKI for dialysis-requiring patients is greater than 295 cases per million per 
year (1, 2). AKI complications are observed in 1-9% of hospital inpatients, with 40% of 
these patients being admitted to the intensive care unit due to AKI complications; more 
than 60% of patients in the intensive care unit have some sort of AKI episode during 
their stay, having 50-70% increased mortality rate (1, 3, 4). AKI can result from a number 
of causes including pre-renal (loss of blood flow to the kidney), post-renal (urinary tract 
obstruction), or intrinsic AKI (4). Intrinsic AKI is the most common form of AKI (4) and 
can be divided into three subcategories: acute glomerular nephritis, acute interstitial 
nephritis, and acute tubular necrosis (4). A common cause of intrinsic kidney injury, 
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specifically acute tubular necrosis, is nephrotoxic pharmaceutical agents, which account 
for 55-60% of hospital inpatient AKI cases (4). There are a number of pharmaceutical 
agents including many antibiotics and anti-cancer chemotherapeutics that have a severe 
side effect of nephrotoxicity. Cisplatin (cis-diamminedichloridoplatinum(II)) is a 
commonly used chemotherapeutic in the treatment of many solid tumor cancers such as 
head and neck, bladder, ovarian, lung, and testicular cancers (5-7). Cisplatin is a simple, 
small, inorganic platinum-based drug (5-7). It induces cell death by binding DNA, leading 
to the formation of intra- and inter-strand crosslinks (6, 7); this can result in the formation 
of faulty DNA templates, leading to cell cycle arrest and ultimately cell death. Cancer 
cells are particularly susceptible to the cytotoxic mechanism of action of cisplatin largely 
because they are rapidly dividing, which increases the likelihood of cisplatin binding to 
DNA and eliciting its cytotoxic action. Cisplatin is eliminated through renal excretion, 
where it is metabolized to a nephrotoxic metabolite and consequently has a dose-limiting 
side effect of nephrotoxicity (5, 8-10) observed in over 30% of patients administered 
cisplatin (10).  
Cisplatin, once metabolized to its nephrotoxic metabolite, induces a myriad of 
physiological responses in the kidney resulting in kidney injury and ultimately kidney 
failure (5, 9-12). While some of the processes involved in cisplatin-induced 
nephrotoxicity are understood, many are not well elucidated and there are no 
renoprotective strategies for protecting the kidney from cisplatin (nor any other 
nephrotoxic agent). For this reason, patients suffering from cisplatin-induced kidney 
injury must be removed from cisplatin treatment or placed on a lower dose, resulting in 
the ineffective treatment of their cancers. Thus, there is still a clear need to gain a better 
understanding of the mechanisms by which cisplatin causes nephrotoxicity so that novel 
targets can be identified for the development of renoprotective strategies. This would 
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widen the therapeutic window of cisplatin in cancer treatment, making it more effective at 
reducing tumor burden.  
Cisplatin is accumulated in the kidney at concentrations five-times higher than 
those observed in serum (9). In the kidney, cisplatin is concentrated primarily within the 
proximal tubules of the nephron (5, 8-10).  Cisplatin enters the proximal tubular portion 
of the nephron in a number of ways. One way cisplatin enters the proximal tubule is via 
glomerular filtration in part because of cisplatin’s small size (9, 10). Cisplatin is also a 
known substrate for at least two transporters, the organic cation transporter-2 (OCT2) 
and copper transporter-1 (CTR1), which are both expressed basolaterally on proximal 
tubule cells (5, 9, 12, 13). OCT2 expression is higher in the kidney than any other tissue 
in the body (14). It has been shown both in vivo and in vitro that cisplatin is a substrate 
for OCT2; importantly, inhibition of OCT2 with cimetidine or knockdown of OCT2 
protects against cisplatin-induced injury both in vitro and in vivo (14-16). Once cisplatin 
enters the proximal tubule cells through these transporters it is transported into the 
lumen of the proximal tubule where it is metabolized to a nephrotoxic metabolite. The 
transporter responsible for the efflux of cisplatin out of proximal tubule cells into the 
lumen is the multidrug extrusion transporter-1 (MATE-1), which is found of the apical 
surface of proximal tubule cells (17). 
The metabolism of cisplatin to a nephrotoxic metabolite is a multistep process 
that first begins with the conjugation of cisplatin to glutathione (5, 8-10). LLC-PK1 cells 
treated with the cisplatin-glutathione conjugates have significantly less viability than 
unconjugated cisplatin treated cells (8). Thus, cisplatin-glutathione conjugates are more 
nephrotoxic than unconjugated cisplatin, suggesting that cisplatin is in fact metabolized 
to a more nephrotoxic chemical species. Cisplatin-glutathione conjugates are substrates 
for gamma-glutamyl transpeptidase (GGT) (8), an enzyme expressed on the apical 
surface of proximal tubule cells. GGT is responsible for the metabolism of cisplatin-
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glutathione conjugates to form a cisplatin-cysteinyl-glycine-conjugate, a substrate for 
aminodipeptidase (8, 18). Aminodipeptidase is another enzyme highly expressed on the 
apical surface of proximal tubule cells, and is responsible for the cleavage of the 
cisplatin-cysteinyl-glycine-conjugate to a cisplatin-cysteinyl-conjugate. The metabolites 
formed following aminodipeptidase reactions are substrates for cysteine-conjugate E-
lyase (19), an enzyme found intracellularly in renal proximal tubular cells. Thus, 
cysteinyl-conjugates are metabolized by cysteine-conjugate E-lyase to form a reactive 
thiol conjugate (13, 20, 21). Inhibition of either GGT or cysteine-conjugate E-lyase 
resulted in protection from cisplatin induced cell death in vitro,  indicating that the 
reactive thiol conjugate formed after the cysteine-conjugate E-lyase catalyzed reaction is 
the final nephrotoxic metabolite of cisplatin (8, 22). 
Due to the complexity of cisplatin’s nephrotoxic mechanism of action, the 
development of renoprotective agents remains a challenge. In the kidney, cisplatin is 
metabolized to its nephrotoxic metabolite, which induces kidney injury and ultimately 
kidney failure (5, 9-12). Cisplatin-induced nephrotoxicity involves several biological 
responses, including mitochondrial dysfunction, activation of cell death pathways, 
generation of reactive oxygen species, and the mounting of a robust inflammatory 
response (5, 10). At lower concentrations, cisplatin induces apoptosis, whereas at higher 
concentrations it induces necrosis (9, 11, 23). Both mitochondrial dysfunction and cell 
death have been shown to be up and downstream of the induction of inflammatory 
pathways, which act to further perpetuate cisplatin-induced kidney injury (24-26). 
The inflammatory response associated with cisplatin-induced AKI is known to 
have many components such as production of inflammatory cytokines and chemokines, 
activation of resident macrophages, and infiltration of immune cells into the kidney (10, 
12). Many pro-inflammatory cytokines and chemokines have been implicated in cisplatin-
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induced AKI, such as tumor necrosis factor- α  (TNF-α), interleukin-1β (IL-1β), 
interleukin-6 (IL-6), and monocyte chemotactic protein (MCP-1) (10, 12).  TNF-α has 
been shown to be a major mediator of kidney injury following cisplatin treatment. 
Inhibition of TNF-α synthesis or use of a neutralizing TNF-α antibody attenuates 
cisplatin-induced AKI in rodents (26, 27). Mice deficient in TNF-α as well as TNF-α 
receptor-1 deficient mice are protected from cisplatin-induced kidney injury (26, 27). 
While a role for TNF-α is well established, the role of other cytokines and chemokines in 
cisplatin-induced AKI is not well established. Cytokine production (IL-1β, IL-18, and IL-6) 
following cisplatin treatment is in part mediated via caspase 1 (28). While caspase 1-
knockout mice have decreased production of IL-1β, IL-18, or IL-6 following cisplatin 
treatment and are protected from cisplatin-induced AKI. Specific inhibition IL-1β, IL-18, 
or IL-6 was insufficient to protect mice from cisplatin-induced AKI (28). The chemokine 
(C-X-C motif) ligand 1 (CXCL1) has also been implicated in the pathogenesis of 
cisplatin-induced AKI as CXCL1 receptor-deficient mice are protected from cisplatin-
induced AKI (29). Many of these recent studies, among many others in the literature, 
only inhibit one arm of the inflammatory response; however an agent that can 
antagonize multiple arms of the inflammatory response may be an invaluable 
renoprotective approach for cisplatin-induced AKI. 
Interestingly, purinergic type 2 (P2) receptors have been implicated in many arms 
of the inflammatory response. Both dying cells and damaged tissue release ATP as 
danger signals, which elicit an inflammatory response (30). P2 receptors recognize 
danger signals including ATP and play a crucial role in inducing activation of the 
inflammatory response (30). P2 receptors are known to be expressed on multiple 
inflammatory cell types such as mast cells, T cells, macrophages, and neutrophils (30), 
which have all been shown to infiltrate the kidney during cisplatin-induced AKI (10, 12). 
More specifically, P2 receptors in macrophages play a role in macrophage spreading 
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and chemotaxis (30) and regulate the activation of caspase-1, leading to the production 
of the pro-inflammatory cytokines IL-18 and IL-1β (30, 31). P2 receptors are expressed 
not only on inflammatory cells, but also in every tissue in the body. There are many P2 
receptor subtypes that are expressed in renal proximal tubule cells, the main site of 
cisplatin-induced injury in the kidney, and/or the inflammatory cell types involved in the 
inflammatory response associated with cisplatin. For example, P2Y6 is expressed in 
renal proximal tubule cells and is known to be involved in the release of many 
chemokines and cytokines (30, 32). This receptor along with other P2 receptor subtypes 
such as P2Y2, P2Y12, and P2X7 have been implicated in the recruitment of monocytes, 
macrophages, and neutrophils (30, 32), all of which infiltrate the kidney following 
treatment with cisplatin (12). Since P2 receptors play a regulatory role in chemotaxis and 
the production of pro-inflammatory cytokines and are located in proximal tubule cells, 
their inhibition may prove to be protective from cisplatin-induced AKI.  
Suramin, a pan P2 receptor antagonist, is a polysulfonated napthylurea 
compound originally designed for the treatment of trypanosomiasis. Eichhorst et al. have 
previously demonstrated that pretreatment or co-administration of suramin with fulminant 
protects mice from liver damage via inhibition of death receptor-induced apoptosis (33). 
Suramin has also been shown to speed recovery in rodent models of kidney diseases 
(34-40). In diabetic nephropathy, unilateral ureteral obstruction, and the remnant kidney, 
post-treatment of suramin was shown to dampen the inflammatory response and reverse 
the associated fibrotic phenotypes (34-40). Also, in ischemia/ reperfusion and glycerol-
induced AKI, suramin post-treatment improves recovery by dampening the inflammatory 
response and promoting renal proximal tubule cell proliferation (35). A role for the P2 
receptors in cisplatin-induced AKI has not been examined and suramin has never been 
tested in models of cisplatin-induced AKI. Likewise, it is unknown if prophylactically 
blocking the P2 receptors with suramin will reduce kidney injury. We hypothesized that 
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inhibition of the P2 receptors would attenuate the inflammatory response upon cisplatin 
treatment and protect the kidney from injury.  
To test this hypothesis, we inhibited the P2 receptors via suramin and then 
treated mice with cisplatin. Renal function, pathology, inflammation, and markers of cell 
death were assessed. Our data presented below indicate that pretreatment with suramin 
protects the kidney from cisplatin as evidenced by improved markers of renal function, 






MATERIAL AND METHODS 
 
Reagents and Antibodies 
The following antibodies were purchased from Cell Signaling: inositol requiring enzyme 
1a (IRE1α; Cat. No. 3294), Cleaved Caspase 3 (Cat. No. 9664), Cleaved Caspase 8 
(Cat. No. 9252), C/EBP-homologous protein (CHOP; Cat. No. 2895), c-Jun N-terminal 
kinases (JNK; Cat. No. 9258), p-JNK (Cat. No. 4668), proliferating cell nuclear antigen 
(PCNA; Cat. No. 13100), and phosphorylated histone H2Ax (Cat. No. 9718). and β-actin 
were purchased from Santa Cruz (Dallas, TX). Both Suramin (S2671) and Cisplatin 
(P4394) were purchased from Sigma Aldrich (St. Louis, MO) 
Animals 
C57BL/6j mice were purchased from The Jackson Laboratory (Bar Harbor, ME) at 8 
weeks of age and experimentation was started at 9 weeks. All mice were maintained on 
a 12-hour light/ 12-hour dark cycle and provided food and water ad libitum. Animals were 
maintained under standard laboratory conditions. All animal procedures were approved 
by the Institutional Animal Care and Use Committee and followed the guidelines of the 
American Veterinary Medical Association.  Suramin (1 or 10 mg/ kg) in PBS (200 μL / 
animal) was administered by tail vein injection 72 h prior to cisplatin. Cisplatin at 20 mg/ 
kg in PBS (200 μL / animal) was administered by i.p. injection. Forty-eight hours after 
cisplatin injection, mice were put into metabolic cages for urine collection for 24 h and 
then euthanized. Blood was drawn and serum prepared and stored at -80°C. The 
kidneys were flash frozen in liquid nitrogen or fixed in 10 % neutral buffered formalin. 
Eight to ten month old FVB mice expressing mutant driven lung tumors were obtained as 
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a gift from Dr. Levi Beverly. These bi-transgenic mice were made by crossing CCSP-rtTa 
activator mice to Tet-op-K-rasG12D.  Genotyping was performed via PCR as described 
previously (41). 
BUN and Serum Creatinine 
Blood Urea Nitrogen (BUN, DIUR-500)) and Serum Creatinine (C7548-120), were 
determined using kits from Bioassay Systems (Hayward, CA) and Point Scientific Inc. 
(Canton, MI), respectively following the manufactures’ instructions.  
Protein Quantification, Western Analysis, and ELISAs 
Homogenates were made from kidney cortex by homogenization in 20 mM HEPES 
buffer containing a Complete Protease Inhibitor Cocktail Tablet and Phosphatase 
Inhibitor Cocktail Tablets (Roche, Indianapolis, IN). Homogenates were centrifuged at 
15,000 X g for 10 min at 4° C.  Supernatants were removed, mixed, aliquotted, and 
stored at -80°C until use. Protein concentrations were determined using Bradford 
Reagent (Bio-Rad, Hercules CA). Kidney homogenate (40 μg) was separated on 4–12% 
gradient Tris-Glycine-SDS polyacrylamide gels and transferred to PVDF membranes 
that were blocked in 5% (w/v) dried milk in tris buffered saline containing 0.1% (v/v) 
Tween 20 (TBST) for 1 h. Membranes were incubated with 1:1000 dilutions of primary 
antibody overnight at 4°C. The next morning, membranes were washed 3 times for 5 min 
each with TBST containing 5 % (w/v) dried milk. After incubation for 2 h at room 
temperature with secondary antibodies conjugated with horseradish peroxidase 
(1:10,000, in TBST containing 1.25% (w/v) dried milk), membrane proteins were 
detected by chemiluminiscence substrate. ELISAs for kidney injury molecule-1 (KIM-1) 
(DT1817, R&D systems, Minneapolis, MN) and neutrophil gelatinase associated lipocalin 




Total RNA was isolated using RNA-STAT 60 (TEL-TEST Inc., Friendswood, TX) using 
mini-Bead-beater glass beads and mini Bead Beater machine (Cole-Palmer, Vernon 
Hills, IL).  Other than using the bead beater glass bead to disrupt the tissue, we used the 
protocol provided by RNA-STAT 60 manufacturer.  cDNA was made from 1 µg of total 
RNA using iScript cDNA synthesis Kit (Bio-Rad) following manufacturers’ instructions.  
Gene specific cDNAs were quantitated using real-time PCR using either Sybr green or 
predesigned TaqMan assays. Primers used in real-time PCR reaction quantitated by 
Sybr green were designed such that each primer set bound to exons separated by an 
intron of at least 600 bp to minimize the likelihood of genomic DNA amplification.  Melt 
curve analysis was also performed to ensure only one PCR product was being amplified.  
Transcripts quantitated using Sybr green included TNFα (5’-aatggcctccctctcatcagtt-3’ 
and 5’-ccacttggtggtttgctacga-3’) and the housekeeping gene for normalization B2M (5’-
ttctggtgcttgtctcactga-3’ and 5’-cagtatgttcggcttcccattc-3’) using Sso Fast Evagreen 
Supermix (Bio-Rad) following manufacturer’s instruction. Chemokine (C-X-C) ligand-1 
(Cxcl1; Mm04207460_m1), Chemokine (C-C) ligand-2 (Ccl2 or Mcp1; 
Mm00441242_m1), Interleukin-1E (Il1E; Mm0043228_m1), Interleukin-6 (IL6; 
Mm00446190_m1) were purchased from Life Technologies (Grand Island NY) and used 
in combination with 2x Gene expression Master Mix (Life Technologies).  Primers for 
quantitation of hepatitis A cellular receptor-1 (Havcr1 or Kim-1) were purchased from 
Bio-Rad and used in combination with Sso Advance Universal Probe Master Mix (Bio-
Rad) following manufacturer’s instruction. 
Histology 
Kidney sections (5 Pm) were stained with hematoxylin and eosin and periodic acid schiff 
(PAS), and the degree of morphologic changes was determined by light microscopy in a 
blinded fashion. The following measures were chosen as an indication of morphologic 
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damage to the kidney after treatment with vehicle, suramin 10 mg/ kg, cisplatin 20 mg/ 
kg, or cisplatin and suramin 10 mg/ kg: proximal tubule dilation, brush-border damage, 
proteinaceous casts, interstitial widening, and necrosis. These measures were evaluated 
on a scale from 0 to 4, which ranged from not present (0), mild (1), moderate (2), severe 
(3), and very severe (4). Lung sections (5 Pm) from animals 48 h after cisplatin 
administration were stained with hematoxylin and eosin and PAS.  
Immunohistochemistry 
Lung sections were rehydrated in xylene followed by an ethanol gradient. Antigen 
retrieval was performed in citric acid buffer pH 6.0 at 95 °C in a steamer for 30 min. 
Endogenous peroxidases were inhibited with 3% hydrogen peroxide for 10 min, followed 
by two 5-minute PBS washes. Slides were blocked with 5% normal goat serum in 0.1% 
TBST for 1 h at room temperature. Anti- phosphorylated H2A.x (aka γH2A.x) (1:480) in 
5% normal goat serum containing TBST was added to sections and incubated overnight 
at 4 °C. The following morning, slides were washed three times with PBS for 5 minutes 
each. Biotinylated goat anti-rabbit IgG antibody (1:200) (Vector laboratories, BA-1000) 
was added to each section and incubated for 30 minutes at room temperature. Slides 
were then rinsed twice with PBS (5 minutes each). Vector ABC reagent (Vector 
laboratories, PK-7100) was added to each section and incubated for 30 minutes at room 
temperature. Slides were rinsed twice with PBS, followed by the addition horse-radish 
peroxidase (HRP), which was detected with NovaRed Substrate (Vector Laboratories, 
SK-4800; added to each section for 10 minutes). Slides were rinsed in tap water for 5 
minutes, counterstained with modified mayer’s hematoxylin (thermo scientific, 72804), 
followed by dehydration in an ethanol gradient to xylene and mounting with Permount 
(Fisher Scientific, SP15).  
Cell Viability 
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A549 cells were maintained in Dulbecco's modified Eagle's medium, high glucose, and 
5% (v/v) fetal bovine serum (FBS). A549 cells seeded in 96-well dishes (5,000 cells per 
well) were treated with either cisplatin (P4394, Sigma-Aldrich, St. Louis, MO) alone or 
cisplatin plus 50 µM suramin (S2671, Sigma-Aldrich) 48 h after plating in a total volume 
of 200 µl per well. All treatments were done in triplicate. Cells were incubated for 24 h 
and 10% (v/v) (20 µl) Alamar Blue reagent (DAL1100) (Invitrogen, Grand Island, NY) 
was added. Plates were then incubated for 4 h and the fluorescence of Alamar Blue 
reduction determined on a BioTek HT Synergy plate reader (540 nm excitation, 594 nm 
emission). Wells containing only complete DMEM media and vehicle plus 20 µl of 
Alamar Blue were averaged and subtracted from all experimental readings. Drug 
treatment regimens were then normalized to either vehicle treated cells or to wells 
containing only 50 µM Suramin. Each graph shown is a representative experiment of at 
least three biological replicates, with error bars representing standard error of the mean.  
Statistical Analysis Data  
Data are expressed as means ± standard error of the mean (SEM) for all the 
experiments. Multiple comparisons of normally distributed data were analyzed by two-
way ANOVA, as appropriate, and group means were compared using Bonferroni post-
tests. For western blot analysis, densitometry was performed using ImageJ software 
from the NIH. Data were normalized to the loading control and multiple comparisons of 
normally distributed data were analyzed by one-way ANOVA, as appropriate, and group 
means were compared using Tuckey post-tests. Single comparisons were analyzed by 
Student’s t-test where appropriate. The criterion for statistical differences was p < 0.05 






Effect of suramin pretreatment on serum and urine indicators of AKI in cisplatin 
treated mice. Suramin has been utilized in many models of kidney injury, both acute 
and chronic, as an agent that improves recovery from injury or fibrosis when given after 
disease onset (34-40); however, suramin has never before been used prophylactically to 
protect from kidney injury. Mice were pre-treated with suramin (1 mg/ kg and 10 mg/ kg) 
72 h prior to cisplatin (20 mg/ kg) administration then sacrificed 72 h after cisplatin 
administration. As shown in Figure 1, cisplatin treated mice had significantly increased 
levels of BUN (217 ± 27 mg/ dL), serum creatinine (0.83 ± 0.07 mg/ dL ), urinary NGAL 
(4.2 × 107 ± 1.09 × 107 pg/ mL), urinary Kim-1 (104,050 ± 12,429 pg/ mL), and renal Kim-
1 mRNA expression (3977 ± 699 ) as compared to vehicle treated animals (Figure 1) 
that indicated decreased renal function and injury. Mice pre-treated with 10 mg/ kg 
suramin prior to cisplatin had significantly decreased levels of BUN (99.27 ± 7.67 mg/ 
dL), serum creatinine (0.517 ± 0.037 mg/ dL), urinary NGAL (1.6×107 ± 4.9×106  pg/ mL), 
urinary Kim-1 (43,334±13,573 pg/mL), and renal Kim-1 gene expression (1,669±1,013); 
however, mice pre-treated with 1 mg/kg suramin prior to cisplatin did not show a 
significant decrease in the above kidney injury markers (Figure 1). These data indicate 
that pre-treatment of mice with 10 mg/ kg suramin is sufficient to reduce kidney injury 
resulting from cisplatin,  while pretreatment of mice with 1 mg/ kg suramin did not. 
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Figure 1. Pretreatment with high dose suramin improves markers of kidney 
function and injury. C57BL/6j mice were pre-treated with suramin (1mg/ kg, S1 or 10 
mg/ kg, S10) or vehicle control via i.v. through the tail vein 72 h prior to cisplatin 
administration (20 mg/ kg, i.p.) and mice were sacrificed 72 h after cisplatin 
administration. Levels of  (A) blood urea nitrogen (BUN) and (B) serum creatinine were 
assessed via colorimetric assay and enzymatic assays, respectively. Urinary (C) NGAL 
and (D) Kim-1 levels were assessed via an ELISA assay. mRNA expression of (E) Kim-1 
in the kidney cortex was assessed via real time qRT-PCR. n = 10; data are the mean ± 
the SEM. * indicates p ≤ 0.05 as compared to cisplatin treated group as determined by a 
two-way ANOVA.  V indicates vehicle control, S1 indicates suramin i.v. pre-treatment at 
1mg / kg, S10 indicates suramin i.v. pre-treatment at 10mg / kg, C indicates cisplatin i.p. 
at 20 mg / kg, CS1 indicates Suramin i.v. pre-treatment at 1 mg / kg followed by cisplatin 
i.p. at 20 mg/ kg 72 h later, CS10 indicates Suramin i.v. pre-treatment at 10 mg / kg 
followed by cisplatin i.p. at 20 mg/ kg 72 h later. 



















































































Effect of suramin pretreatment on pathological damage to proximal tubules in 
cisplatin treated mice. In order to determine if the kidney injury markers measured in 
Figure 1 were associated with renal histological changes, we assessed renal histology 
on hematoxylin and eosin (H&E) and periodic acid schiff (PAS) stained paraffin 
embedded sections collected 72 h after cisplatin administration. A renal pathologist 
blindly scored the following markers of proximal tubule histological damage as described 
in the methods: (B) acute tubular necrosis, (C) loss of brush border, (D) proximal tubular 
cast formation, (E) tubule dilation, and (F) degeneration. As indicated in Figure 2, all of 
the above markers were significantly increased in cisplatin treated mice. On the contrary, 
these histological changes were significantly attenuated in the mice pretreated with 
suramin at 10 mg/ kg (Figure 2). Thus, suramin protected mice from histological damage 














Figure 2. Suramin prevents cisplatin-induced deterioration in kidney pathology.  
Renal histological changes were assessed on H&E and PAS stained sections (5μM) 
thick. (A) Representative images of renal histology at 200X magnification. (B) Tubular 
necrosis, (C) loss of proximal tubule brush borders, (D) proximal tubule cast formation, 
(E) proximal tubule dilation, and (F) degredation were assessed as markers of 
histological changes. For figures (B-F), scoring of the sections was performed in a 
blinded manner by renal pathologist Dr. Megyesi using a scale of 0-4 (0=not present, 
1=mild, 2=moderate, 3=severe, and 4=very severe renal histological changes in the 
proximal tubules). n = 10; data are the mean ± the SEM. * indicates p ≤ 0.05 as 
compared to cisplatin treated group as determined by a two-way ANOVA.  V indicates 
vehicle control, S10 indicates suramin i.v. pre-treatment at 10 mg / kg, C indicates 
cisplatin i.p. at 20 mg / kg, CS10 indicates Suramin i.v. pre-treatment at 10 mg / kg 
followed by cisplatin i.p. at 20 mg/ kg 72 h later. 
* 
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Effect of suramin pretreatment on inflammatory cytokines and chemokines in 
mice treated with cisplatin. Treatment with cisplatin has been shown to induce the 
expression of many pro-inflammatory cytokines in the kidney (12, 28, 29). In Figure 3, 
we assessed mRNA expression of the following pro-inflammatory cytokines and 
chemokines such as: (a) Tnf-α, (b) Il6, (c) Cxcl-1, (d) Mcp-1, and (e) Il1β. All of the 
aforementioned cytokines and chemokines were significantly elevated 10.8 ± 2.7, 66 ± 
10, 144 ± 20, 15.2 ± 4.5, and 3.41 ± 0.60-fold respectively over the vehicle treated 
control mice with 20 mg/ kg cisplatin treatment; however, mice pre-treated with suramin 
(10 mg/ kg) 72 h prior to cisplatin treatment had significantly reduced mRNA expression 
2.8 ± 0.5, 9.8 ± 3.4, 19.5 ± 6.9, 2.7 ± 0.9, and 0.7 ± 0.1 of these pro-inflammatory 
cytokines and chemokines, respectively (Figure 3). These data demonstrated that 
pretreatment of mice with suramin reduces cisplatin-induced expression of pro-
inflammatory cytokines and chemokines in the kidney. 
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Figure 3. Suramin pre-treatment reduces inflammation in the kidney following 
cisplatin treatment. C57BL/6j mice were pre-treated with suramin (1 mg/kg or 10 mg/kg 
or equal volume vehicle) via tail vein injection 72 h prior to cisplatin administration 
(20mg/kg, i.p.). Mice were sacrificed 72 h after cisplatin administration and relative 
expression of (A) Tnfα, (B) Il6, (C) Cxcl1, (D) Mcp1, and (E) Il1β were measured via real-
time qRT-PCR. data are the mean ± the SEM. * indicates p ≤ 0.05 as compared to 
cisplatin treated group as determined by a two-way ANOVA. For all panels, V indicates 
vehicle control, S1 indicates suramin i.v. pre-treatment at 1 mg/kg, S10 indicates 
suramin i.v. pre-treatment at 10mg/kg, C indicates cisplatin i.p. at 20 mg/kg, CS1 
indicates Suramin i.v. pre-treatment at 1 mg/kg followed by cisplatin i.p. at 20 mg/kg 72 h 
later, CS10 indicates Suramin i.v. pre-treatment at 10 mg / kg followed by cisplatin i.p. at 
20 mg/ kg 72 h later.
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Effect of suramin pretreatment on markers of cell stress and proliferation in 
cisplatin treated mice. The kidney is known to activate a number of pathways in 
response to cisplatin-induced injury, including cell stress and proliferation signaling 
pathways (12). Thus, we assessed markers of cell stress and proliferation that are 
associated with cisplatin-induced AKI. Cisplatin treated mice had significantly increased 
levels of the activated form of pJNK (96.8 ± 18.0) compared to vehicle treatment, while 
the pretreatment with 10 mg/ kg suramin significantly decreased levels of pJNK 
(19.7±5.8) compared to cisplatin treatment alone (Figure 4A and B).  We also assessed 
markers of endoplasmic reticulum stress (ER Stress), as it has previously been 
implicated in cisplatin-induced AKI.  Cisplatin treatment increased both IRE1α (6.2 ± 0.9) 
and CHOP (7.1 ± 1.2) expression, while cisplatin plus suramin treatment decreased both 
IRE1α (2.4±0.2) and CHOP (3.7±1.1) expression; while IRE1α was significantly 
decreased with suramin treatment prior to cisplatin, CHOP expression exhibited a 
decreasing trend compared to cisplatin alone treated animals (Figure 4A and B). Finally, 
PCNA, a marker of proliferation, had increased expression (11.8 ± 2.3) with cisplatin 
treatment but was significantly decreased with cisplatin plus suramin treatment (0.5 ± 
0.2). Taken together, these data indicate that suramin pre-treatment decreases cisplatin-




Figure 4. Suramin prevents cisplatin-induced increases in markers of cell stress 
responses and proliferation. Western blot analysis was performed to assess relative 
protein levels of the indicated proteins in the renal cortex of vehicle treated mice (V), 
cisplatin treated mice (C), and suramin pre-treated (10 mg/ kg i.v.) mice that were given 
cisplatin (20 mg/ kg) 72 h later (CS10).  Samples from the kidney cortex were prepared 
from mice sacrificed  72 hours after cisplatin administration. For B-E, densitometry was 
performed to assess relative protein levels normalized to actin. For B-E, data are the 
mean ± SEM and * indicates statistically significant difference as compared to cisplatin 
treated group as determined by one-way ANOVA. n = 5  
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Effect of suramin pretreatment on markers of apoptosis in cisplatin treated mice.  
Cisplatin treatment is known to induce apoptosis in the kidney (12). Thus, we assessed 
markers of apoptosis in the kidney cortex. Apoptosis is dependent on activation and 
cleavage of cysteine and aspartate proteases (caspases). In Figure 5 (A-C),  western 
blot and the corresponding densitometry analysis of kidney cortex protein homogenates 
show that cisplatin treatment of mice caused 11.2 ± 2.4 and 13.4 ± 1.4 -fold increases in 
the levels of cleaved caspase 8 and cleaved caspase 3, respectively. Suramin plus 
cisplatin treated mice had significantly reduced levels of cleaved caspases 8 and 3 in the 
kidney cortex, with 0.5 ± 0.2 and 5.2 ± 2.1, respectively. These data indicate that 










Figure 5. Pretreatment with suramin inhibits cisplatin-induced cell death in the 
kidney. C57BL/6j mice were pre-treated with suramin (10 mg / kg, i.v.) or vehicle control 
72 h prior to cisplatin (20 mg / kg, i.p.) and mice were sacrificed after an additional 72 h. 
(A) Western blot analysis of cleaved caspase 8 and cleaved caspase 3 from 
homogenates of kidney cortex for the following treatment groups: Vehicle (V), cisplatin 
(C), Cisplatin +Suramin 10 mg/kg (CS10). For B and C, densitometry was performed to 
assess relative protein levels normalized to actin. For B and C data are the mean ± SEM 
and * indicates statistically significant difference as compared to cisplatin treated group 
as determined by one-way ANOVA.  
C. Casp 3 
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Effect of suramin pre-treatment and cisplatin on mutant Kras lung cancer mice.  
Cisplatin-induced reduction in tumor mass is dependent on its ability to induce DNA 
damage and apoptosis. If suramin is to be utilized with cisplatin as part of a treatment 
protocol, then it cannot directly reduce cisplatin-induced apoptosis in cancer cells. We 
assessed the effects of suramin on the tumoricidal activity of cisplatin both in vitro and in 
vivo.  A549 cells, a non-small cell lung cancer cell line expressing mutant KRAS, were 
pre-treated with 50 μM suramin for 1 h, then treated with cisplatin (0-135 μM, 48 h) 
(Figure 6A). We chose to pretreat A549 cells with 50 μM because 50 μM suramin is 
known to induce renal proximal tubule cell proliferation and scattering (42). Thus 50 μM 
suramin is a concentration that may provide renoprotective effects against cisplatin-
induced kidney injury. There was no difference in the dose response curves of the 
cisplatin-treated A549 cells with or without 50 μM suramin pre-treatment. To examine the 
in vivo effects of suramin, FVB mice expressing doxycline-inducible mutant Kras driven 
lung adenocarcinoma were treated with cisplatin alone or pretreated with suramin 72 h 
prior to cisplatin. Levels of BUN were measured as a marker of kidney function. BUN 
levels were significantly higher in mice treated with cisplatin compared to mice pre-
treated with suramin (10 mg/ kg) 72 h prior to cisplatin (Figure 6B). The ability of cisplatin 
to induce DNA damage in the lung adenocarcinomas in the presence and absence of 
suramin was evaluated by performing immunohistochemistry of γ-H2A.x staining in lung 
sections. Studies have found an association between γ-H2A.x activation, and reduced 
cell viability (43, 44). In Figure 6C, we observed significant increase in γ-H2A.x staining 
in the lung nodules of cisplatin treated mice compared to vehicle treated animals. The 
lung nodules from mice receiving suramin pre-treatment prior to cisplatin showed no 
difference in γ-H2A.x staining compared to the staining in cisplatin only treated mice 
(Figure 6C). Figure 6D depicts H&E stained lung sections for the visualization of the 
tumor surrounded by adjacent normal tissue. Taken together, these data suggest that 
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suramin pre-treatment protects mice from cisplatin-induced AKI without inhibiting the 





Figure 6. Suramin treatment does not prevent the anti-tumor efficacy of cisplatin. 
(A) A549 cells were treated with 0-135 μM cisplatin in the presence and absence of 1 
μM suramin for 24 h. Cell viability was assessed via Alamar Blue assay. (B) BUN levels 
of 10-month old FVB mice harboring mutant Kras driven lung tumors treated with 10 
mg/kg suramin 72 h prior to cisplatin treatment (20 mg/kg). Mice were sacrificed 48h 
after cisplatin administration. Immunohistochemistry of (C) γH2A.x and (D) H&E Stained 
lung sections from mice in B. V indicates vehicle control, S1 indicates suramin i.v. pre-
treatment at 1 mg/kg, S10 indicates suramin i.v. pre-treatment at 10mg/kg, C indicates 
cisplatin i.p. at 20 mg/kg, CS1 indicates Suramin i.v. pre-treatment at 1 mg/kg followed 
by cisplatin i.p. at 20 mg/kg 72 h later, CS10 indicates Suramin i.v. pre-treatment at 10 
mg/kg followed by cisplatin i.p. at 20 mg/ kg 72 h later. * indicates statistically significant 
difference as compared to cisplatin treated group as determined by two-way ANOVA. n 


































Previous studies have shown that treatment with suramin after the onset of 
kidney injury accelerates recovery from injury (35, 38, 40); however, suramin has never 
before been used prophylactically to protect from kidney injury. The use of suramin in a 
model of cisplatin-induced AKI also has never before been studied. Thus, in this study 
we focus on the prophylactic use of suramin as a renoprotective agent against the 
pathogenesis of cisplatin-induced AKI. Our results indicate that suramin protects mice 
from cisplatin-induced AKI at 10 mg/kg, but not at a lower dose of 1 mg/ kg. Markers of 
kidney function and injury were improved in mice treated with the higher dose of 
suramin. Data indicated that suramin attenuated the inflammatory response associated 
with cisplatin-induced AKI, and also with decreased markers of cell stress and 
proliferation in the renal cortex following cisplatin administration. Suramin also 
decreased cisplatin-induced induced death receptor and/ or intrinsic apoptosis as 
evidenced by lower levels of cleaved caspases 8 and 3 in the kidney cortex. 
Interestingly, our in vitro data suggested that the protection observed in vivo may not be 
mediated by suramin directly blocking kidney cell death as BMK cells pretreated with 1 
μM suramin were not protected from cisplatin-induced reduction in cell numbers. 
Likewise, suramin did not attenuate reduced cell viability in A549 lung cancer cells 
treated with cisplatin. Finally, suramin pre-treatment (10 mg/ kg) of FVB mice harboring 
mutant Kras driven lung adenocarcinomas were protected from cisplatin-induced AKI as 
evidenced by improved BUN. However, suramin did not block the ability of cisplatin to 
induce DNA damage in the lung adenocarcinomas. Taken together, our data suggest 
that suramin pre-treatment prior to cisplatin administration protects the kidney from 
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cisplatin-induced AKI without inhibiting cisplatin’s cytotoxic activity. These data suggest 
that suramin may be efficacious for widening the therapeutic window of cisplatin for the 
treatment of lung cancer.  
Suramin has been shown to attenuate the inflammatory response associated 
with the disease progression in multiple models of both AKI and chronic kidney disease 
(CKD) (34, 35, 37, 38). Interestingly, suramin is a pan purinergic P2 receptor antagonist, 
and P2 receptors are known to play a regulatory role in the mounting of an inflammatory 
response following tissue injury (30, 31, 45). A myriad of P2 receptors are expressed on 
both the proximal tubule cells (32, 46) and leukocytes (30) involved in the pathogenesis 
of cisplatin-induced AKI. P2 receptors are known to play a regulatory role in the release 
of cytokines and chemokines such as MCP-1 and CXCL-1 (47-49). Interestingly, in our 
studies, we found that expression of both MCP-1 and CXCL-1, both of which are pro-
inflammatory chemokines and cytokines respectively, are decreased following cisplatin 
treatment in mice that were pre-treated with suramin. Our data indicate that suramin pre-
treatment also decreases the renal expression of TNFα, IL-1β, and IL-6 mRNA. Mast 
cells have been implicated in the pathogenesis of cisplatin-induced AKI and are known 
to release pro-inflammatory cytokines upon degranulation including TNF-α, IL-1β, and 
IL-6 (12, 50). Suramin has been shown to inhibit mast cell degranulation (51), which may 
be a mechanism by which it inhibits expression of these cytokines that are known to 
perpetuate kidney injury.  
It has been shown that during cisplatin-induced AKI, TNF-α signals through TNF-
α receptor (TNFR) for the activation of many cell stress and cell death pathways during 
cisplatin-induced AKI (10, 12, 26, 27). TNF-α signaling through TNFR has been shown 
to induce phosphorylation of JNK, which participates in ER stress and apoptosis (52-54). 
ER stress-induced apoptosis plays a role in cisplatin-induced AKI (5). During cisplatin-
induced AKI, renal cells are under stress as a result of increased cellular damage, which 
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leads to activation of ER stress-mediated pathways. IRE1α is activated during ER stress 
and signals through JNK for the cells to undergo ER stress-induced apoptosis (53, 55). 
Our results indicate that cisplatin treatment increases IRE1α and JNK activation, while 
pre-treatment with suramin decreases cisplatin-induced IRE1α expression and pJNK. 
Interestingly, this is not the only pathway of ER stress that mediates apoptosis. CHOP is 
a transcription factor, which is associated with activating ER stress-induced apoptosis 
independently of IRE1α and JNK (55). We found that CHOP expression was significantly 
decreased with pre-treatment of suramin prior to cisplatin. These results suggest that 
suramin protects from ER stress-induced apoptosis; however, there are many other 
pathways of apoptosis implicated in cisplatin-induced AKI.   
Cisplatin administration has been shown to induce many pathways of cell death 
including both apoptosis and necrosis (5, 10, 12). During cisplatin-induced AKI, many 
pathways of apoptosis are activated, including the death receptor mediated pathway of 
apoptosis (5, 10, 12). In this pathway of apoptosis, TNF-α or other death receptor 
ligands can activate death receptors on the proximal tubule cell surface leading to 
caspase 8 cleavage and activation followed by the cleavage and activation of 
downstream effector caspases such as caspase 3, leading to apoptosis (52). Suramin 
has been shown to inhibit TNF-α from binding with the death receptor (33). Interestingly 
our results show that pre-treatment with suramin prior to cisplatin treatment significantly 
decreases both caspase 8 and caspase 3 cleavage, suggesting that suramin is 
preventing cisplatin-induced death receptor-mediated apoptosis in the kidney, while 
suramin pretreatment also decreased the renal expression of TNF-α in mice treated with 
cisplatin. On the contrary, we found that suramin does not inhibit cell death induced 
directly by cisplatin in a lung cancer cell line. Thus, our in vivo and in vitro data suggest 
that suramin protects from cisplatin-induced AKI through the attenuation of the 
inflammatory response.  
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More importantly, suramin is currently being pursued for the treatment of many 
cancers as a single agent and in combination therapy with many anti-cancer 
chemotherapeutic agents including cisplatin (56-59). Our data also indicate that suramin 
does not inhibit cisplatin’s cytotoxic efficacy. These data indicate that the use of suramin 
to attenuate cisplatin-induced AKI has great translational potential. In future studies, it 
will be important to determine if suramin post-treatment following cisplatin is sufficient to 
speed recovery from cisplatin-induced AKI. Elucidating an optimal dosing regimen for 

























Cisplatin, a commonly used chemotherapeutic in the treatment of many solid 
tumor cancers has a dose limiting side effect of nephrotoxicity. There are currently no 
treatment options for AKI besides palliative care. Thus, there is a clear need for the 
development of renoprotective strategies in the treatment/prevention of cisplatin-induced 
AKI. In this study, we utilized an FDA approved drug, suramin, which has been shown to 
speed recovery from multiple models of kidney injury encompassing both acute and 
chronic kidney disease.  
It was observed that pretreatment with suramin at a high dose (10 mg/ kg) prior 
to cisplatin treatment protected from cisplatin-induced AKI, while a low dose of suramin 
(1 mg/ kg) did not exhibit renoprotective effects against cisplatin-induced AKI. Pre-
treatment with suramin at 10 mg/ kg prior to cisplatin treatment attenuated the gene 
expression of pro-inflammatory cytokine mRNAs associated with the pathogenesis of 
cisplatin-induced AKI. It was also found that suramin pre-treatment prior to cisplatin 
treatment decreased markers of cell stress and proliferation. Suramin pre-treatment also 
decreased death receptor mediated apoptosis following cisplatin administration. In vitro 
experiments indicated that suramin pre-treatment does not protect from cell death 
induced directly by cisplatin in kidney cells, suggesting that suramin’s renoprotective 
effects are most likely through the attenuation of the inflammatory response. Finally, 
suramin pre-treatment prior to cisplatin administration protected mice harboring mutant 
Kras-driven lung tumors from cisplatin-induced kidney injury, while not inhibiting 
cisplatin’s tumoricidal efficacy.  
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In conclusion, the data obtained from this study indicate that suramin has great 
potential to be repurposed as a renoprotective agent to protect patients from cisplatin-
induced AKI. Thus, the use of suramin as a renoprotective agent will potentially widen 
the therapeutic window of cisplatin, enabling patients to receive more effective treatment 
of their cancer, which will hopefully improve their prognosis and quality of life while 
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